Dupuytren's contracture as result of prolonged administration of phenobarbital.

Risultato della ricerca: Article

8 Citazioni (Scopus)

Abstract

Dupuytren's disease is a fibroproliferative condition involving the superficial palmar fascia, leading to a progressive and irreversible flexion of the fingers. In literature, there are different opinions regarding the phenobarbital, a common antiepileptic drug, and its effective role in the genesis and development of Dupuytren's disease. In this retrospective investigation the association between phenobarbital and Dupuytren's contracture is discussed.Three patients in treatment with phenobarbital who had no others significant risk factors for Dupuytren's contracture were included in this study. The disease occurred after one to four years of drug therapy, at dosage of 100 mg/day. After surgery, Dupuytren's disease showed different evolutions in relation to dosage and type of antiepileptic drug used. Phenobarbital causes a dose and time-dipendent profibrotic effect. A clinical regression was observed when phenobarbital was substituted by carbamazepine, maintaining the same dosage (100 mg/day). This data confirms that not all the antiepileptic drugs are implicated in palmar fibrosis, and suggests that, according to the efficacy and adverse effects, the administration of benzodiazepine reduces the risk of Dupuytren's recurrence.
Lingua originaleEnglish
pagine (da-a)299-302
Numero di pagine4
RivistaEUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
Volume15
Stato di pubblicazionePublished - 2011

Fingerprint

Dupuytren Contracture
Phenobarbital
Anticonvulsants
Subcutaneous Tissue
Carbamazepine
Benzodiazepines
Fingers
Fibrosis
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cita questo

@article{014af3ba4c94448d985edb7b78693064,
title = "Dupuytren's contracture as result of prolonged administration of phenobarbital.",
abstract = "Dupuytren's disease is a fibroproliferative condition involving the superficial palmar fascia, leading to a progressive and irreversible flexion of the fingers. In literature, there are different opinions regarding the phenobarbital, a common antiepileptic drug, and its effective role in the genesis and development of Dupuytren's disease. In this retrospective investigation the association between phenobarbital and Dupuytren's contracture is discussed.Three patients in treatment with phenobarbital who had no others significant risk factors for Dupuytren's contracture were included in this study. The disease occurred after one to four years of drug therapy, at dosage of 100 mg/day. After surgery, Dupuytren's disease showed different evolutions in relation to dosage and type of antiepileptic drug used. Phenobarbital causes a dose and time-dipendent profibrotic effect. A clinical regression was observed when phenobarbital was substituted by carbamazepine, maintaining the same dosage (100 mg/day). This data confirms that not all the antiepileptic drugs are implicated in palmar fibrosis, and suggests that, according to the efficacy and adverse effects, the administration of benzodiazepine reduces the risk of Dupuytren's recurrence.",
author = "Adriana Cordova and Francesco Moschella",
year = "2011",
language = "English",
volume = "15",
pages = "299--302",
journal = "EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES",
issn = "1128-3602",

}

TY - JOUR

T1 - Dupuytren's contracture as result of prolonged administration of phenobarbital.

AU - Cordova, Adriana

AU - Moschella, Francesco

PY - 2011

Y1 - 2011

N2 - Dupuytren's disease is a fibroproliferative condition involving the superficial palmar fascia, leading to a progressive and irreversible flexion of the fingers. In literature, there are different opinions regarding the phenobarbital, a common antiepileptic drug, and its effective role in the genesis and development of Dupuytren's disease. In this retrospective investigation the association between phenobarbital and Dupuytren's contracture is discussed.Three patients in treatment with phenobarbital who had no others significant risk factors for Dupuytren's contracture were included in this study. The disease occurred after one to four years of drug therapy, at dosage of 100 mg/day. After surgery, Dupuytren's disease showed different evolutions in relation to dosage and type of antiepileptic drug used. Phenobarbital causes a dose and time-dipendent profibrotic effect. A clinical regression was observed when phenobarbital was substituted by carbamazepine, maintaining the same dosage (100 mg/day). This data confirms that not all the antiepileptic drugs are implicated in palmar fibrosis, and suggests that, according to the efficacy and adverse effects, the administration of benzodiazepine reduces the risk of Dupuytren's recurrence.

AB - Dupuytren's disease is a fibroproliferative condition involving the superficial palmar fascia, leading to a progressive and irreversible flexion of the fingers. In literature, there are different opinions regarding the phenobarbital, a common antiepileptic drug, and its effective role in the genesis and development of Dupuytren's disease. In this retrospective investigation the association between phenobarbital and Dupuytren's contracture is discussed.Three patients in treatment with phenobarbital who had no others significant risk factors for Dupuytren's contracture were included in this study. The disease occurred after one to four years of drug therapy, at dosage of 100 mg/day. After surgery, Dupuytren's disease showed different evolutions in relation to dosage and type of antiepileptic drug used. Phenobarbital causes a dose and time-dipendent profibrotic effect. A clinical regression was observed when phenobarbital was substituted by carbamazepine, maintaining the same dosage (100 mg/day). This data confirms that not all the antiepileptic drugs are implicated in palmar fibrosis, and suggests that, according to the efficacy and adverse effects, the administration of benzodiazepine reduces the risk of Dupuytren's recurrence.

UR - http://hdl.handle.net/10447/56072

M3 - Article

VL - 15

SP - 299

EP - 302

JO - EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES

JF - EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES

SN - 1128-3602

ER -